Preclinical assets consist of various types of services such as Bioanalysis and DMPK (Drug Metabolism and pharmacokinetics) studies, which are further sub segmented into in vitro and in vivo analysis, toxicology testing, which are based on GLP and non GLP (Good Laboratory Practices), compound management process R&D (Research and development), custom synthesis, asymmetric synthesis, and others (Scale-up, cGMP (current good manufacturing practices), safety pharmacology. Preclinical assets have two types of models, patient derived organoid (PDO) model and patient derived xenograft model.
Market Dynamics
Increasing number of service launch in preclinical testing by the key market players is expected to drive growth of the global preclinical assets market during the forecast period. For instance, in July 2020, Skinobs, a cosmetic company, announced the launch of a new preclinical testing platform skinobs, an independent tool which provides a 360-degree vision of in vivo efficacy testing. This platform enables users to identify and select the testing methods depending on various criteria such as
- Test Category: which include analytical tests, content-contenair interaction, ecotoxicity and biodegradability tests, safety tests, UV (Ultra Violet ) tests, etc.
- Claim: which include anti-ageing, anti-pollution, etc.
- Test support: which include cell cultures, 3D skin models, etc.
Similarly, in December 2021, Sirona Medical, a software company, announced the launch of its cloud-native radiology operating system (RadOS) optimizing the use of novel AI (Artificial Intelligence) applications in clinical practice at the 2021 Annual Meeting for Radiological Society of North America (RSNA). The platform was based on the combination of technology and artificial intelligence, which would help augment the intelligence of the physician in clinical practices.
Key features of the study:
- This report provides an in-depth analysis of the global preclinical assets market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2022 – 2030, considering 2021 as the base year
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the global preclinical assets market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
- Key players covered as a part of this study include Eurofins Scientific, ICON plc, WuXi AppTec, Viroclinics Xplore, Medpace, Inc., Charles River Laboratories., Pharmatest Services, PPD Inc., SGS SA (SGS), Intertek Group plc, Labcorp Drug Development, Laboratory Corporation of America, Inc., Crown Bioscience, Comparative Biosciences, Inc., TCG Lifesciences Private Limited., Shanghai Medicilon Inc., Domainex, Absorption Systems, AmplifyBio, and IQVIA
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global preclinical assets market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, suppliers, research and consulting firms, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global preclinical assets market
Detailed Segmentation:
- Global Preclinical Assets Market, By Service:
- Bioanalysis and DMPK studies
- Toxicology Testing
- Compound Management
- Process R&D
- Custom Synthesis
- Asymmetric Synthesis
- Others (Scale-up, cGMP, etc.)
- Safety Pharmacology
- Others (Chemistry, etc.)
- Global Preclinical Assets Market, By Model Type:
- Patient Derived Organoid (PDO) Model
- Patient derived xenograft model
- Global Preclinical Assets Market, By End User:
- Biopharmaceutical Companies
- Government Institutes
- Others (Academic and Research institutes)
- Global Preclinical Assets Market, By Region:
- North America
- Latin America
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Country
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
- By Country
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Middle East
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Country/Region
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Eurofins Scientific*
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- ICON plc
- WuXi AppTec
- Viroclinics Xplore
- Medpace, Inc.
- Charles River Laboratories.
- Pharmatest Services
- PPD Inc.
- SGS SA (SGS)
- Intertek Group plc
- Labcorp Drug Development
- Laboratory Corporation of America, Inc.
- Crown Bioscience
- Comparative Biosciences, Inc.
- TCG Lifesciences Private Limited.
- Shanghai Medicilon Inc.
- Domainex
- Absorption Systems
- AmplifyBio
- IQVIA
“*” marked represents similar segmentation in other categories in the respective section.
